OpenAI公司AGI（通用人工智能）开发负责人Fidji Simo因确诊神经免疫系统疾病，即将开始医疗休假。这位高管近期被诊断出患有影响神经系统的免疫相关病症，需要专注进行治疗和康复。
根据公开信息，Simo在OpenAI负责领导前沿的AGI技术研发团队。此次休假期间，其职责将由公司内部核心管理层暂代。OpenAI表示将全力支持Simo的康复计划，并相信其专业团队能确保AGI研发工作的持续推进。
神经免疫疾病是一类免疫系统异常攻击神经组织的病症，临床表现具有多样性。企业高管因健康原因暂离岗位在科技行业并非罕见，多家硅谷公司都曾有过类似案例。业界关注此事是否会对OpenAI的AGI战略布局产生潜在影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.